<?xml version="1.0" encoding="UTF-8"?>
<p id="p0055">Chloroquine has also been tested in chronic viral diseases. Its use in the treatment of HIV-infected patients has been considered inconclusive (
 <xref rid="bib1" ref-type="bibr">Chauhan and Tikoo, 2015</xref>) and the drug has not been included in the panel recommended for HIV treatment. The only modest effect of chloroquine in the therapy of human virus infection was found for chronic hepatitis C: an increase of the early virological response to pegylated interferon plus ribavirin (
 <xref rid="bib12" ref-type="bibr">Helal et al., 2016</xref>) and, in a small sample size pilot trial in non-responder HCV patients, a transient viral load reduction (
 <xref rid="bib22" ref-type="bibr">Peymani et al., 2016</xref>) were observed. This was not enough to include chloroquine in the standardised therapeutic protocols for hepatitis C patients.
</p>
